Skip to main content
Top
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients

Authors: Xiang Zheng, Jing Zhou, Baozhen Zhang, Jun Zhang, James Wilson, Liankun Gu, Budong Zhu, Jin Gu, Jiafu Ji, Dajun Deng

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

CBX7 is a Polycomb group protein that shows variable expression changes in various cancers that are often contradictive. A mouse knockout experiment has validated the tumor suppressor role in carcinogenesis. The purpose of this study is to verify the tumor suppressor role of Cbx7 in human colon carcinomas (CC).

Methods

Frozen CC and the surgical margin (SM) tissue samples from patients (n = 97) were obtained from the Peking University Cancer Hospital. All patients had follow-up data for at least three years. The level of Cbx7 mRNA and protein was determined by quantitative RT-PCR, immunohistochemistry and Western blot, respectively. The association between Cbx7 mRNA level and clinicopathological characteristics of CC patients was then statistically analyzed.

Results

CBX7 expression changes detected through immunohistochemistry and Western blot in 10 pairs of representative CC samples significantly correlated with their corresponding mRNA levels when Alu, but not GAPDH, was used as the endogenous reference control in quantitative RT-PCR. The Alu-normalized Cbx7 mRNA levels were significantly increased in SM tissues when compared with CC tissues or colon biopsies taken from non-cancer patients (Student’s t-test, P < 0.036 or 0.007). Furthermore, decreased levels of Cbx7 mRNA positively correlated with lymph metastasis (P = 0.029). Overall survival (OS) of CC patients classified as Cbx7 expression-low was considerably shorter than those classified as Cbx7 expression-high (Hazard ratio = 2.97, 95% CI [1.68 ~ 5.25]; P <0.001). Multiple variant analyses showed that the Cbx7 expression-low was an independent predictor of short OS (Hazard ratio = 3.16, 95% CI [1.58-6.30]; P < 0.001).

Conclusion

Cbx7 is downregulated in CCs, and Cbx7 expression-low tumors correlated with lymph metastasis and poor overall survival of CC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009;10(10):697–708.CrossRefPubMed Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009;10(10):697–708.CrossRefPubMed
2.
go back to reference Forzati F, Federico A, Pallante P, Abbate A, Esposito F, Malapelle U, et al. CBX7 is a tumor suppressor in mice and humans. J Clin Invest. 2012;122(2):612–23.CrossRefPubMedPubMedCentral Forzati F, Federico A, Pallante P, Abbate A, Esposito F, Malapelle U, et al. CBX7 is a tumor suppressor in mice and humans. J Clin Invest. 2012;122(2):612–23.CrossRefPubMedPubMedCentral
3.
go back to reference Scott CL, Gil J, Hernando E, Teruya-Feldstein J, Narita M, Martinez D, et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A. 2007;104(13):5389–94.CrossRefPubMedPubMedCentral Scott CL, Gil J, Hernando E, Teruya-Feldstein J, Narita M, Martinez D, et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A. 2007;104(13):5389–94.CrossRefPubMedPubMedCentral
4.
go back to reference Bernard D, Martinez-Leal JF, Rizzo S, Martinez D, Hudson D, Visakorpi T, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene. 2005;24(36):5543–51.CrossRefPubMed Bernard D, Martinez-Leal JF, Rizzo S, Martinez D, Hudson D, Visakorpi T, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene. 2005;24(36):5543–51.CrossRefPubMed
5.
go back to reference Zhang XW, Zhang L, Qin W, Yao XH, Zheng LZ, Liu X, et al. Oncogenic role of the chromobox protein CBX7 in gastric cancer. Journal of Experimental & Clinical Cancer Research: CR. 2010;29:114–21.CrossRefPubMedCentral Zhang XW, Zhang L, Qin W, Yao XH, Zheng LZ, Liu X, et al. Oncogenic role of the chromobox protein CBX7 in gastric cancer. Journal of Experimental & Clinical Cancer Research: CR. 2010;29:114–21.CrossRefPubMedCentral
6.
go back to reference Shinjo K, Yamashita Y, Yamamoto E, Akatsuka S, Uno N, Kamiya A, et al. Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. Int J Cancer. 2014;135(2):308–18.CrossRefPubMed Shinjo K, Yamashita Y, Yamamoto E, Akatsuka S, Uno N, Kamiya A, et al. Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. Int J Cancer. 2014;135(2):308–18.CrossRefPubMed
7.
go back to reference Karamitopoulou E, Pallante P, Zlobec I, Tornillo L, Carafa V, Schaffner T, et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer. 2010;46(8):1438–44.CrossRefPubMed Karamitopoulou E, Pallante P, Zlobec I, Tornillo L, Carafa V, Schaffner T, et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer. 2010;46(8):1438–44.CrossRefPubMed
8.
go back to reference Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 2008;68(16):6770–8.CrossRefPubMed Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 2008;68(16):6770–8.CrossRefPubMed
9.
go back to reference Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, Schostak M, et al. Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine. 2008;29(5):323–9.CrossRef Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, Schostak M, et al. Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine. 2008;29(5):323–9.CrossRef
10.
go back to reference Forzati F, Federico A, Pallante P, Fedele M, Fusco A. Tumor suppressor activity of CBX7 in lung carcinogenesis. Cell Cycle. 2012;11(10):1888–91.CrossRefPubMed Forzati F, Federico A, Pallante P, Fedele M, Fusco A. Tumor suppressor activity of CBX7 in lung carcinogenesis. Cell Cycle. 2012;11(10):1888–91.CrossRefPubMed
11.
go back to reference Pallante P, Terracciano L, Carafa V, Schneider S, Zlobec I, Lugli A, et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer. 2010;46(12):2304–13.CrossRefPubMed Pallante P, Terracciano L, Carafa V, Schneider S, Zlobec I, Lugli A, et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer. 2010;46(12):2304–13.CrossRefPubMed
12.
go back to reference Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10(6):353–8.CrossRefPubMed Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10(6):353–8.CrossRefPubMed
13.
go back to reference Guan ZP, Gu LK, Xin BC, Ji JF, Gu J, Deng DJ. Downregulation of chromobox protein homolog 7 expression in multiple human cancer tissues (in Chinese). Chin J Prev Med. 2011;45(7):597–600. Guan ZP, Gu LK, Xin BC, Ji JF, Gu J, Deng DJ. Downregulation of chromobox protein homolog 7 expression in multiple human cancer tissues (in Chinese). Chin J Prev Med. 2011;45(7):597–600.
14.
go back to reference Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21(1):19–22.CrossRefPubMed Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21(1):19–22.CrossRefPubMed
15.
go back to reference Li Q, Wang X. Polycomb CBX7 Directly Controls Trimethylation of Histone H3 at Lysine 9 at the P16 Locus. PLoS One. 2010;5(10):1–15. Li Q, Wang X. Polycomb CBX7 Directly Controls Trimethylation of Histone H3 at Lysine 9 at the P16 Locus. PLoS One. 2010;5(10):1–15.
16.
go back to reference Marullo M, Zuccato C, Mariotti C, Lahiri N, Tabrizi SJ, Di Donato S, et al. Expressed Alu repeats as a novel, reliable tool for normalization of real-time quantitative RT-PCR data. Genome Biol. 2010;11(1):R9.CrossRefPubMedPubMedCentral Marullo M, Zuccato C, Mariotti C, Lahiri N, Tabrizi SJ, Di Donato S, et al. Expressed Alu repeats as a novel, reliable tool for normalization of real-time quantitative RT-PCR data. Genome Biol. 2010;11(1):R9.CrossRefPubMedPubMedCentral
17.
go back to reference Vandesompele J, Preter KD, Pattyn F, Poppe B, Roy NV, Paepe AD, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):0034.0031.CrossRef Vandesompele J, Preter KD, Pattyn F, Poppe B, Roy NV, Paepe AD, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):0034.0031.CrossRef
18.
go back to reference Żyżyńska-Granica B, Koziak K. Identification of suitable reference genes for real-time PCR analysis of statin-treated human umbilical vein endothelial cells. PLoS One. 2012;7(12), E51547.CrossRefPubMedPubMedCentral Żyżyńska-Granica B, Koziak K. Identification of suitable reference genes for real-time PCR analysis of statin-treated human umbilical vein endothelial cells. PLoS One. 2012;7(12), E51547.CrossRefPubMedPubMedCentral
19.
go back to reference Xiang S, Liu Z, Zhang B, Zhou J, Zhu BD, Ji J, et al. Methylation status of individual CpG sites within Alu elements in the human genome and Alu hypomethylation in gastric carcinomas. BMC Cancer. 2010;10:44.CrossRefPubMedPubMedCentral Xiang S, Liu Z, Zhang B, Zhou J, Zhu BD, Ji J, et al. Methylation status of individual CpG sites within Alu elements in the human genome and Alu hypomethylation in gastric carcinomas. BMC Cancer. 2010;10:44.CrossRefPubMedPubMedCentral
20.
go back to reference Suzuki T, Higgins PJ, Crawford DR. Control selection for RNA quantitation. Biotechniques. 2000;29:332–7.PubMed Suzuki T, Higgins PJ, Crawford DR. Control selection for RNA quantitation. Biotechniques. 2000;29:332–7.PubMed
21.
go back to reference Bustin SA. Absolute Quantification Of mRNA Using Real-Time Reverse Transcription Polymerase Chain Reaction Assays. J Mol Endocrinol. 2000;25(2):169–93.CrossRefPubMed Bustin SA. Absolute Quantification Of mRNA Using Real-Time Reverse Transcription Polymerase Chain Reaction Assays. J Mol Endocrinol. 2000;25(2):169–93.CrossRefPubMed
Metadata
Title
Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients
Authors
Xiang Zheng
Jing Zhou
Baozhen Zhang
Jun Zhang
James Wilson
Liankun Gu
Budong Zhu
Jin Gu
Jiafu Ji
Dajun Deng
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1172-6

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine